{"entity":{"id":"paper-froeling-pstt-ett-intensified-therapy-bjc-2019","kind":"paper","name":"Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours","aka":[],"tldr":"An updated UK series of placental-site and epithelioid trophoblastic tumours found that more intensive treatment, including high-dose chemotherapy for the worst-prognosis women, improved survival, and refined the factors that predict outcome.","summary":"Retrospective analysis of 125 women with placental-site or epithelioid trophoblastic tumour treated in the UK trophoblastic disease centres, extending the earlier Charing Cross series.\n\nSurvival improved in the later period with intensified platinum-based chemotherapy and, for women with an interval of 48 months or more since the antecedent pregnancy, high-dose chemotherapy with stem cell rescue; stage, interval and other factors such as hCG level and metastatic pattern were prognostic.","asOf":"2026-09-18","links":[{"label":"Br J Cancer 2019","url":"https://doi.org/10.1038/s41416-019-0402-0"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/30792530/"}],"tags":[],"related":[],"cancers":["placental-site-trophoblastic-tumour"],"sections":[],"technologies":[],"targets":[],"drugs":["etoposide","cisplatin","paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["british-journal-of-cancer"],"dependsOn":[],"notes":[],"journal":"British Journal of Cancer","year":2019,"doi":"10.1038/s41416-019-0402-0","pmid":"30792530","authors":"Froeling FEM, Ramaswami R, Papanastasopoulos P, et al.","paperType":"observational","findings":["Survival improved in the more recent treatment era with intensified therapy.","Interval of 48 months or more from the antecedent pregnancy remained the dominant adverse factor, with high-dose chemotherapy offering some long-term survivors."],"whatItMeans":"Women with poor-prognosis placental-site or epithelioid trophoblastic tumours should be referred to a specialist centre where intensified and experimental treatments, including immunotherapy, are available.","caveats":["Retrospective, with treatment changing over time.","Small numbers in the high-dose chemotherapy group."],"changedPractice":true,"participants":125},"route":"/key-papers/paper-froeling-pstt-ett-intensified-therapy-bjc-2019/","neighbours":{"cancer":[{"id":"placental-site-trophoblastic-tumour","kind":"cancer","name":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","route":"/cancers/placental-site-trophoblastic-tumour/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"journal":[{"id":"british-journal-of-cancer","kind":"journal","name":"British Journal of Cancer","route":"/journals/british-journal-of-cancer/"}]}}